|
Jun 23
|
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 17
|
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
|
|
Jun 15
|
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 4
|
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
|
|
Jun 4
|
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
|
|
May 30
|
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
|
|
May 30
|
Intellia stock dips following safety event in Phase III gene therapy trial
|
|
May 29
|
Intellia stock tumbles on safety concerns
|
|
May 29
|
Intellia filing spurs safety concerns over CRISPR drug
|
|
Apr 22
|
Trump’s FDA Sends a Bullish Signal to Biotech
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Apr 4
|
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
|
|
Apr 3
|
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility
|
|
Apr 3
|
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
|
|
Apr 1
|
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Mar 31
|
Intellia Focuses on Pipeline Development Amid Stiff Competition
|
|
Mar 1
|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|